Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
|
US |
|
Capital Product Partners LP
NASDAQ:CPLP
|
GR |
Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals Inc. emerged on the healthcare scene with a mission deeply rooted in a poignant reality: the need for tailored cancer treatments for children. Named symbolically to reflect the fresh start they aspire to offer to young patients, Day One focuses on developing and commercializing targeted therapies specifically for pediatric cancer, a field historically overlooked by the larger pharmaceutical industry. The company employs innovative drug development strategies, utilizing molecular targeted therapy—a precise approach that zeroes in on cancer cells while sparing healthy ones. This methodology not only underscores their commitment to efficacy and safety but also positions them as pioneers in an area rife with unmet medical needs.
Fundamentally, the company generates its revenue through the successful commercialization of its therapies. It channels resources into robust clinical trials to demonstrate the efficacy and safety of its drugs, seeking regulatory approvals as key milestones. Licensing deals also play a crucial role in its business model, as partnerships with larger pharmaceutical firms enable Day One to expand its reach and scale. This strategic blending of in-house development and external alliances allows Day One to navigate the complex biopharmaceutical landscape efficiently, driving both innovation and financial sustainability. As they continue to advance their pipeline, the company aims to reshape pediatric oncology, demonstrating that profitable ventures can indeed be built around noble societal missions.
Day One Biopharmaceuticals Inc. emerged on the healthcare scene with a mission deeply rooted in a poignant reality: the need for tailored cancer treatments for children. Named symbolically to reflect the fresh start they aspire to offer to young patients, Day One focuses on developing and commercializing targeted therapies specifically for pediatric cancer, a field historically overlooked by the larger pharmaceutical industry. The company employs innovative drug development strategies, utilizing molecular targeted therapy—a precise approach that zeroes in on cancer cells while sparing healthy ones. This methodology not only underscores their commitment to efficacy and safety but also positions them as pioneers in an area rife with unmet medical needs.
Fundamentally, the company generates its revenue through the successful commercialization of its therapies. It channels resources into robust clinical trials to demonstrate the efficacy and safety of its drugs, seeking regulatory approvals as key milestones. Licensing deals also play a crucial role in its business model, as partnerships with larger pharmaceutical firms enable Day One to expand its reach and scale. This strategic blending of in-house development and external alliances allows Day One to navigate the complex biopharmaceutical landscape efficiently, driving both innovation and financial sustainability. As they continue to advance their pipeline, the company aims to reshape pediatric oncology, demonstrating that profitable ventures can indeed be built around noble societal missions.
Revenue Growth: Day One reported 2025 net product revenue of $155.4 million, up 172% year-over-year, driven by strong uptake of OJEMDA.
OJEMDA Momentum: OJEMDA prescriptions grew over 180% YoY in 2025, with more than 4,600 total prescriptions and robust physician enthusiasm.
Guidance Reiterated: Management maintained 2026 OJEMDA net product revenue guidance of $225–250 million, implying over 50% YoY growth at the midpoint.
Strong Financial Position: The company ended 2025 with $441 million in net cash and no debt, providing flexibility for future investments.
Clinical Milestones: Three-year data from the FIREFLY-1 trial showed durable efficacy and no new safety signals for OJEMDA; full enrollment for the FIREFLY-2 trial is expected in the first half of 2026.
Pipeline Expansion: Acquisition of Mersana Therapeutics added the Emi-Le antibody drug conjugate to the pipeline, with an update expected mid-2026, and DAY301 progress continues.
Persistency Focus: Median duration of therapy for OJEMDA is trending toward 19 months; management identified opportunities to further improve patient persistence.
Payer Dynamics: Over 95% of pLGG patients are receiving paid drug, with more than 90% approved on the first request, supporting efficient therapy initiation.
